Education
About Us
Working with TipRanks
Follow Us
Instil Bio, Inc. (TIL)
NASDAQ:TIL
TIL Stock Chart & Stats
$8.90
-$1.87(-8.00%)
At close: 4:00 PM EST
$8.90
-$1.87(-8.00%)
Day’s Range― - ―
52-Week Range$5.67 - $42.79
Previous CloseN/A
Volume80.17K
Average Volume (3M)37.99K
Market Cap
$57.99M
Enterprise Value$137.10M
Total Cash (Recent Filing)$79.67M
Total Debt (Recent Filing)$84.92M
Price to Earnings (P/E)―
Beta5.12
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,781,976
10 Day Avg. Volume24,388
30 Day Avg. Volume37,986
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.89
Enterprise Value/Market Cap2.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-182.08
Enterprise Value/Ebitda-2.05
Forecast
1Y Price Target
$7.00Price Target Upside-21.35% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-5.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Burn OutlookReported cash levels support the view that cash burn should contract materially, extending runway and reducing pressure to secure additional financing.
Cash PositionReported cash balances provide a downside cushion and position the company as a cash-backed option as management evaluates strategic alternatives.
Strategic Alternatives PotentialManagement evaluating strategic alternatives could lead to a sale, licensing deal, or asset transaction that unlocks value above the cash base.
Bears Say
Financing And Dilution RiskWith no clear catalysts to drive a re-rating, cash burn during strategic review raises the risk of dilution if new financing becomes necessary, which would further pressure the stock.
Loss Of Lead AssetTermination of the collaboration eliminated development and commercial rights to the lead PD-L1×VEGF asset, removing the primary source of projected future value.
Pipeline ResetDiscontinuation of the lead program effectively resets pipeline value toward zero, leaving the company without clinical catalysts to support a stock re-rating.
Instil Bio News
TIL FAQ
What was Instil Bio, Inc.’s price range in the past 12 months?
Instil Bio, Inc. lowest stock price was $5.67 and its highest was $42.79 in the past 12 months.
What is Instil Bio, Inc.’s market cap?
Instil Bio, Inc.’s market cap is $57.99M.
When is Instil Bio, Inc.’s upcoming earnings report date?
Instil Bio, Inc.’s upcoming earnings report date is May 07, 2026 which is in 45 days.
How were Instil Bio, Inc.’s earnings last quarter?
Currently, no data Available
Is Instil Bio, Inc. overvalued?
According to Wall Street analysts Instil Bio, Inc.’s price is currently Overvalued.
Does Instil Bio, Inc. pay dividends?
Instil Bio, Inc. does not currently pay dividends.
What is Instil Bio, Inc.’s EPS estimate?
Instil Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Instil Bio, Inc. have?
Instil Bio, Inc. has 6,781,976 shares outstanding.
What happened to Instil Bio, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Instil Bio, Inc.?
Currently, no hedge funds are holding shares in TIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Instil Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.00 (-21.35% Downside)
$7.00 (-21.35% Downside)
Blogger Sentiment
Bullish
TIL Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.62%
12-Months-Change
Fundamentals
Return on Equity
-53.02%
Trailing 12-Months
Asset Growth
-22.30%
Trailing 12-Months
Company Description
Instil Bio, Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
TIL Stock 12 Month Forecast
Average Price Target
$7.00
▼(-21.35% Downside)
Technical Analysis
Zentalis Pharmaceuticals
―
Nkarta
―
ALX Oncology Holdings
―
Surrozen
―
TScan Therapeutics
―